



## HIV Pre-Exposure Prophylaxis

This job aid is for providers prescribing pre-exposure prophylaxis (PrEP) to patients at risk of acquiring HIV. Please refer to the HCV and HIV Provider Training Series for additional information.

**Table 1a: Summary of Clinician Guidance for Daily Oral PrEP Use**

	Sexually-Active Adults and Adolescents <sup>1</sup>	Persons Who Inject Drug <sup>2</sup>
Identifying substantial risk of acquiring HIV infection	Anal or vaginal sex in past 6 months AND any of the following: <ul style="list-style-type: none"> <li>HIV-positive sexual partner (especially if partner has an unknown or detectable viral load)</li> <li>Bacterial STI in past 6 months<sup>3</sup></li> <li>History of inconsistent or no condom use with sexual partner(s)</li> </ul>	HIV-positive injecting partner OR Sharing injection equipment
Clinically eligible	<b>ALL OF THE FOLLOWING CONDITIONS ARE MET:</b> <ul style="list-style-type: none"> <li>Documented negative HIV Ag/Ab test result within 1 week before initially prescribing PrEP</li> <li>No signs/symptoms of acute HIV infection</li> <li>Estimated creatinine clearance <math>\geq 30</math> ml/min<sup>4</sup></li> <li>No contraindicated medications</li> </ul>	
Dosage	<ul style="list-style-type: none"> <li>Daily, continuing, oral doses of F/TDF (Truvada®), <math>\leq 90</math>-day supply OR</li> <li>For men and transgender women at risk for sexual acquisition of HIV: daily, continuing, oral doses of F/TAF (Descovy®), <math>\leq 90</math>-day supply</li> </ul>	
Follow-up care	<p><b>Follow-up visits at least every 3 months to provide the following:</b></p> <ul style="list-style-type: none"> <li>HIV Ag/Ab test and HIV-1 RNA assay, medication adherence and behavioral risk reduction support</li> <li>Bacterial STI screening for MSM and transgender women who have sex with men<sup>3</sup> – oral, rectal, urine, blood</li> <li>Access to clean needles/syringes and drug treatment services for PWID</li> </ul> <p><b>Follow-up visits every 6 months to provide the following:</b></p> <ul style="list-style-type: none"> <li>Assess renal function for patients aged <math>\geq 50</math> years or who have an eCrCl <math>&lt; 90</math> ml/min at PrEP initiation</li> <li>Bacterial STI screening for all sexually-active patients<sup>3</sup> – [vaginal, oral, rectal, urine- as indicated], blood</li> </ul> <p><b>Follow-up visits every 12 months to provide the following:</b></p> <ul style="list-style-type: none"> <li>Assess renal function for all patients</li> <li>Chlamydia screening for heterosexually active women and men – vaginal, urine</li> <li>For patients on F/TAF, assess weight, triglyceride and cholesterol levels</li> </ul>	

<sup>1</sup> adolescents weighing at least 35 kg (77 lb)

<sup>2</sup> Because most PWID are also sexually active, they should be assessed for sexual risk and provided the option of CAB for PrEP when indicated

<sup>3</sup> Sexually transmitted infection (STI): Gonorrhea, chlamydia, and syphilis for MSM and transgender women who have sex with men including those who inject drugs; Gonorrhea and syphilis for heterosexual women and men including persons who inject drugs

<sup>4</sup> estimated creatinine clearance (eCrCl) by Cockcroft Gault formula  $\geq 60$  ml/min for F/TDF use,  $\geq 30$  ml/min for F/TAF use

<sup>1</sup> United States Public Health Service, Centers for Disease Control and Prevention, National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention, Preexposure Prophylaxis Work Group. Preexposure prophylaxis for the prevention of HIV infection in the United States -- 2021 update: a clinical practice guideline. Published online 2021. <https://stacks.cdc.gov/view/cdc/112360>

Figure 2: US Public Health Service Summary Guidance for Cabotegravir Injection PrEP Use<sup>2</sup>

Table 1b: Summary of Clinician Guidance for Cabotegravir Injection PrEP Use

	Sexually-Active Adults	Persons Who Inject Drugs <sup>1</sup>
Identifying substantial risk of acquiring HIV infection	Anal or vaginal sex in past 6 months AND any of the following: <ul style="list-style-type: none"> <li>• HIV-positive sexual partner (especially if partner has an unknown or detectable viral load)</li> <li>• Bacterial STI in past 6 months<sup>2</sup></li> <li>• History of inconsistent or no condom use with sexual partner(s)</li> </ul>	HIV-positive injecting partner OR Sharing injection equipment
Clinically eligible	<b><u>ALL OF THE FOLLOWING CONDITIONS ARE MET:</u></b> <ul style="list-style-type: none"> <li>• Documented negative HIV Ag/Ab test result within 1 week before initial cabotegravir injection</li> <li>• No signs/symptoms of acute HIV infection</li> <li>• No contraindicated medications or conditions</li> </ul>	
Dosage	<ul style="list-style-type: none"> <li>• 600 mg cabotegravir administered as one 3 ml intramuscular injection in the gluteal muscle               <ul style="list-style-type: none"> <li>◦ Initial dose</li> <li>◦ Second dose 4 weeks after first dose (month 1 follow-up visit)</li> <li>◦ Every 8 weeks thereafter (month 3,5,7, follow-up visits etc)</li> </ul> </li> </ul>	
Follow-up care	<p><b><u>At follow-up visit 1 month after first injection</u></b></p> <ul style="list-style-type: none"> <li>• HIV Ag/Ab test and HIV-1 RNA assay</li> </ul> <p><b><u>At follow-up visits every 2 months (beginning with the third injection – month 3) provide the following:</u></b></p> <ul style="list-style-type: none"> <li>• HIV Ag/Ab test and HIV-1 RNA assay</li> <li>• Access to clean needles/syringes and drug treatment services for PWID</li> </ul> <p><b><u>At follow-up visits every 4 months (beginning with the third injection- month 3) provide the following:</u></b></p> <ul style="list-style-type: none"> <li>• Bacterial STI screening<sup>2</sup> for MSM and transgender women who have sex with men<sup>2</sup> – oral, rectal, urine, blood</li> </ul> <p><b><u>At follow-up visits every 6 months (beginning with the fifth injection – month 7) provide the following:</u></b></p> <ul style="list-style-type: none"> <li>• Bacterial STI screening<sup>1</sup> for all heterosexually-active women and men – [vaginal, rectal, urine - as indicated], blood</li> </ul> <p><b><u>At follow-up visits at least every 12 months (after the first injection) provide the following:</u></b></p> <ul style="list-style-type: none"> <li>• Assess desire to continue injections for PrEP</li> <li>• Chlamydia screening for heterosexually active women and men – vaginal, urine</li> </ul> <p><b><u>At follow-up visits when discontinuing cabotegravir injections provide the following:</u></b></p>	

<sup>1</sup> Because most PWID are also sexually active, they should be assessed for sexual risk and provided the option of CAB for PrEP when indicated

<sup>2</sup> Sexually transmitted infection (STI): Gonorrhea, chlamydia, and syphilis for MSM and transgender women who have sex with men including those who inject drugs; Gonorrhea and syphilis for heterosexual women and men including persons who inject drugs

<sup>2</sup> United States Public Health Service, Centers for Disease Control and Prevention, National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention, Preexposure Prophylaxis Work Group. Preexposure prophylaxis for the prevention of HIV infection in the United States -- 2021 update: a clinical practice guideline. Published online 2021. <https://stacks.cdc.gov/view/cdc/112360>